FDA Approves Fibromyalgia Drug
Posted on: Friday, 22 June 2007, 15:10 CDT
The U.S. Food and Drug Administration has approved pregabalin as the first drug to treat fibromyalgia.
The FDA said the drug, which is manufactured by Pfizer Inc. under the name Lyrica, reduces pain and improves daily functions for some patients with fibromyalgia.
Fibromyalgia is typically characterized by chronic pain, muscle stiffness and tenderness.
The disorder, which affects about 3 million to 6 million people in the United States each year, mostly affects women in early-to-middle adulthood.
Studies have shown that patients have decreased pain after taking Lyrica but the mechanism by which Lyrica produces such an effect is unknown, the FDA said in a release.
Lyrica already is approved for treating partial seizures, pain following the rash of shingles and pain associated with diabetes nerve damage, the FDA said.
Source: United Press International
Related Articles
- Strategies For Reducing Painful Breast Cancer Drug Side Effects
- Increasing Diagnosis Rates and Growing Use of Key Agents Such as Pfizer's Lyrica Will Drive Eight Percent Annual Growth in the Fibromyalgia Drug Market Through 2018
- Lyrica Reduced Pain of Fibromyalgia in Patients Regardless of Symptoms of Anxiety or Depression
- Thousands of Women Across Virginia Fight the Pains of Fibromyalgia
- Fibromyalgia Drug Sparks Debate
- New Data Suggest Cymbalta(R) Reduced Pain in Fibromyalgia Patients With and Without Depression
- Fibromyalgia Drug Market Will Nearly Quadruple to $2 Billion By 2016
- Pain Therapeutics Terminates Drug Candidate for the Treatment of Irritable Bowel Syndrome
- Celgene Gets Good News on Blood Disorder Drug; FDA Panel Will Recommend Approval for Revlimid
 |
 |
User Comments (0)
RSS Feeds